Sugi Predict

Sugi Predict / Compounds / Ammonia Solution, Strong

Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5802002

Cc1cc2ccccc2nc1C.N

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.61
▸ STAT3 P40763 3/20 0.61
▸ KDM4E B2RXH2 3/20 0.61
▸ HPGD P15428 2/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ GAA P10253 1/20 0.61
▸ PDE10A Q9Y233 1/20 0.57
▸ MAPT P10636 4/20 0.54
▸ GLA P06280 1/20 0.54
▸ ACHE P22303 1/20 0.54
▸ MBNL1 Q9NR56 1/20 0.50
▸ NQO2 P16083 1/20 0.48
▸ HTT P42858 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ CYP1A2 P05177 5/20 0.47
▸ GPR3 P46089 1/20 0.45
▸ NCF1 P14598 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30486684 0.98 ALDH1A1 (0.63) ALDH1A1STAT3KDM4EHPGDTDP1
SCHEMBL422035 0.98 ALDH1A1 (0.63) ALDH1A1STAT3KDM4EHPGDTDP1
Hydrochloric Acid SCHEMBL7361242 0.95 ALDH1A1 (0.61) ALDH1A1STAT3KDM4EHPGDTDP1
Bromide SCHEMBL27763629 0.95 ALDH1A1 (0.61) ALDH1A1STAT3KDM4EHPGDTDP1
Acridine SCHEMBL28194753 0.93 ALDH1A1 (0.65) ALDH1A1STAT3KDM4EHPGDTDP1
Acetic Acid SCHEMBL28135349 0.86 ALDH1A1 (0.56) ALDH1A1STAT3KDM4EHPGDTDP1
Formamide SCHEMBL1839803 0.86 ALDH1A1 (0.52) ALDH1A1STAT3KDM4EHPGDTDP1
SCHEMBL27691863 0.86 ALDH1A1 (0.52) ALDH1A1STAT3KDM4EHPGDTDP1
Formamide SCHEMBL28060876 0.85 ALDH1A1 (0.50) ALDH1A1STAT3KDM4EHPGDTDP1
Carbamic Acid SCHEMBL28794006 0.85 ALDH1A1 (0.55) ALDH1A1STAT3KDM4EHPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710215-B Phenylethynyl substituted benzenes and heterocycles for the treatment of cancer and uses thereof 肯塔基大学研究基金会 2024-06-04 — — CN claimed
CN-114938648-B Stable bulk polymerized polycycloolefin compositions as three-dimensional printing materials and methods of making same 住友电木株式会社 2023-06-30 — — CN claimed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 — — CN claimed
CN-115710215-A Phenylethynyl substituted benzenes and heterocycles useful in the treatment of cancer and uses thereof 肯塔基大学研究基金会 2023-02-24 — — CN claimed
CN-114938648-A Stable bulk polymerized polycyclic olefin compositions as three-dimensional printing materials and methods of making same 普罗米鲁斯有限责任公司 2022-08-23 — — CN claimed
CN-114144450-A Stable polycycloolefin polymers and inorganic nanocomposites as optical materials 普罗米鲁斯有限责任公司 2022-03-04 — — CN claimed
CN-113490527-A Bicyclic derivatives 瑞士伊兰科动物保健有限公司 2021-10-08 — — CN claimed
CN-111902415-A Pharmaceutical compounds 大冢制药株式会社 2020-11-06 — — CN claimed
US-20180273537-A1 COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-09-27 — — US claimed
CN-115710215-B Phenylethynyl substituted benzenes and heterocycles for the treatment of cancer and uses thereof 肯塔基大学研究基金会 2024-06-04 — — CN disclosed
CN-115650904-B Phenylethynyl substituted benzenes and heterocycles for the treatment of cancer and uses thereof 肯塔基大学研究基金会 2024-05-14 — — CN disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 — — CN disclosed
CN-116848170-A Photoactive bulk polymerized polycycloolefin compositions as optical materials that are shelf-life stable for extended periods of time 普罗米鲁斯有限责任公司 2023-10-03 — — CN disclosed
CN-114938648-B Stable bulk polymerized polycycloolefin compositions as three-dimensional printing materials and methods of making same 住友电木株式会社 2023-06-30 — — CN disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 — — CN disclosed
CN-1906169-A Therapeutic agents I ASTRAZENECA AB (SE) 2007-01-31 — — CN disclosed
EP-1706384-A1 THERAPEUTIC AGENTS I AstraZeneca AB (SE) 2006-10-04 — — EP disclosed
CN-1752855-A Toner and image forming apparatus CANON KK (JP) 2006-03-29 — — CN disclosed
WO-2005066132-A1 THERAPEUTIC AGENTS I ASTRAZENECA AB (SE) 2005-07-21 — — WO disclosed
US-5436240-A Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines THE UPJOHN COMPANY (US) 1995-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180273537-A1 COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES PNCK, TXK, CAMKK1 ALDH1A1 4690/4885STAT3 1451/4885KDM4E 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.